In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia

Gudmar Lonnerholm, Ingrid Thorn, Christer Sundstrom, Britt-Marie Frost, Jonas Abrahamsson, Mikael Behrendtz, Jesper Heldrup, Stefan Jacobsson, AiHong Li, Tor Olofsson, Anna Porwit, Stefan Soderhall, Rolf Larsson, Erik Forestier

Research output: Contribution to journalArticlepeer-review

11 Citations (SciVal)

Abstract

Leukemic cells from 85 children with newly diagnosed precursor B-lineage ALL were tested for in vitro drug sensitivity to a panel of anti-cancer drugs. Minimal residual disease (MRD) was measured by RQ-PCR. There was a significant correlation between MRD day 29 and in vitro sensitivity to prednisolone (p < 0.001) and doxorubicin (p = 0.01 7), drugs administered during induction therapy. In patients with t(12;21) (n = 20), in vitro sensitivity to doxorubicin was an independent factor for MRD <0.1% (p = 0.031; R-2 = 0.66). Thus, data show that in vitro drug sensitivity at diagnosis is correlated to cell kill during induction therapy as measured by MRD day 29. (C) 2008 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)46-53
JournalLeukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
Volume33
Issue number1
DOIs
Publication statusPublished - 2009

Subject classification (UKÄ)

  • Cancer and Oncology

Keywords

  • Doxorubicin
  • Prednisolone
  • 21)
  • t(12
  • MRD
  • In vitro drug resistance
  • Acute lymphoblastic leukemia
  • Childhood

Fingerprint

Dive into the research topics of 'In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this